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Abstract
Background: Optimal post-remission strategy for patients with acute myeloid leukemia (AML) is matter of intense
debate. Recent reports have shown stronger anti-leukemic activity but similar survival for allogeneic stem cell
transplantation (allo-HSCT) from matched sibling donor compared to autologous transplantation (auto-HSCT);
however, there is scarcity of literature confronting auto-HSCT with allo-HSCT from unrelated donor (UD-HSCT),
especially mismatched UD-HSCT.
Methods: We retrospectively compared outcome of allogeneic transplantation from matched (10/10 UD-HSCT)
or mismatched at a single HLA-locus unrelated donor (9/10 UD-HSCT) to autologous transplantation in patients
with AML in first complete remission (CR1). A total of 2879 patients were included; 1202 patients received
auto-HSCT, 1302 10/10 UD-HSCT, and 375 9/10 UD-HSCT. A propensity score-weighted analysis was conducted
to control for disease risk imbalances between the groups.
Results: Matched 10/10 UD-HSCT was associated with the best leukemia-free survival (10/10 UD-HSCT vs
auto-HSCT: HR 0.7, p = 0.0016). Leukemia-free survival was not statistically different between auto-HSCT and 9/10
UD-HSCT (9/10 UD-HSCT vs auto-HSCT: HR 0.8, p = 0.2). Overall survival was similar across the groups (10/10 UD-HSCT
vs auto-HSCT: HR 0.98, p = 0.84; 9/10 UD-HSCT vs auto-HSCT: HR 1.1, p = 0.49). Notably, in intermediate-risk patients, OS
was significantly worse for 9/10 UD-HSCT (9/10 UD-HSCT vs auto-HSCT: HR 1.6, p = 0.049), while it did not differ
between auto-HSCT and 10/10 UD-HSCT (HR 0.95, p = 0.88). In favorable risk patients, auto-HSCT resulted in 3-year
LFS and OS rates of 59 and 78 %, respectively.
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Conclusions: Our findings suggest that in AML patients in CR1 lacking an HLA-matched sibling donor, 10/10
UD-HSCT significantly improves LFS, but this advantage does not translate in better OS compared to auto-HSCT.
In intermediate-risk patients lacking a fully HLA-matched donor, auto-HSCT should be considered as a valid option, as
better survival appears to be provided by auto-HSCT compared to mismatched UD-HSCT. Finally, auto-HSCT provided
an encouraging outcome in patients with favorable risk AML.
Keywords: Acute myeloid leukemia (AML), Allogeneic transplantation, Matched (10/10) and mismatched (9/10)
unrelated donor transplantation, Autologous transplantation, Post-remission therapy
Abbreviations: ALWP, Acute leukemia working party; AML, Acute myeloid leukemia; ATT, Average treatment effect
among the treated; auto-HSCT, Autologous stem cell transplantation; BM, Bone marrow; CBF, Core-binding factor;
CEBPA, CCAAT/enhancer-binding protein alpha; CR1, First complete remission; EBMT, European society for blood and
marrow transplantation; ELN, European leukemia net; FLT3-ITD, fms-like tyrosine kinase-internal tandem duplication;
GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto; GVHD, Graft-vs-host disease; GVL, Graft-vs-leukemia;
LFS, Leukemia-free survival; MAC, Myeloablative; MMUD, Mismatched unrelated donor; MRD, Minimal residual disease;
MSD, Matched sibling donor allo-HSCT; MUD, Matched unrelated donor; NCCN, National Comprehensive Cancer
Network; NPM1, Nucleophosmin; NRM, Non-relapse mortality; OS, Overall survival; PBSCs, Peripheral blood stem cells;
PS, Propensity score; RI, Relapse incidence; RIC, Reduced-intensity; TBI, Total-body irradiation; WBC, White blood cells;
wtFLT3, Wild-type FLT3; 10/10 UD-HSCT, Unrelated donor transplantation matched at 10/10 HLA loci; 9/10
UD-HSCT, Unrelated donor transplantation mismatched at a single HLA-locus
Background
Optimal post-remission strategy for patients with acute
myeloid leukemia (AML) is a matter of debate. Allo-
geneic stem cell transplantation (allo-HSCT) is the
most effective treatment to prevent leukemia relapse,
and for patients lacking a matched sibling donor
(MSD), transplantation from a 10/10 matched unrelated
donor (MUD) is the preferred alternative [1]. The indica-
tion for allo-HSCT from 9/10 unrelated donor is more
controversial, and outcome according to patient and dis-
ease characteristics has not been fully established yet [2].
Autologous stem cell transplantation (auto-HSCT) is an
alternative approach, which was initially designed to con-
solidate remission in AML patients lacking a sibling donor
or unfit for allo-HSCT [3]; since then, auto-HSCT passed
through alternate fortunes, and its use progressively
declined following evolution of allo-HSCT protocols
[1, 4, 5]. Nevertheless, auto-HSCT holds several advan-
tages including low non-relapse mortality rates, ab-
sence of graft-vs-host disease (GVHD) risk, lower
incidence of late effects, and better quality of life for
survivors compared to allo-HSCT; concerns include
high relapse rate, due to the absence of graft-vs-
leukemia (GVL) effect and the theoretic possibility of
graft contamination by leukemic cells [6].
Recent reports [7–9] comparing allo-HSCT and auto-
HSCT evidenced similar survival and concluded that
auto-HSCT should still be considered as a valid alterna-
tive to allo-HSCT and taken into account within AML
post-remission strategies. Therefore, since transplants
from unrelated donors (UD) are currently the preferred
option worldwide, and given the lack of a study con-
fronting auto-HSCT with mismatched UD-HSCT, we
took the advantage of the European society for blood
and marrow transplantation (EBMT) data set and
retrospectively compared outcome of matched (10/10
UD-HSCT) or mismatched at a single HLA-locus unre-
lated donor transplantation (9/10 UD-HSCT) with
auto-HSCT in patients with AML in first complete re-
mission (CR1).
Methods
Study design and data collection
This is a retrospective multicenter study. Data were pro-
vided, and the study design was approved by the acute
leukemia working party (ALWP) of the EBMT group
registry, in accordance with the EBMT guidelines for
retrospective studies. EBMT is a voluntary working
group of more than 500 transplant centers which are re-
quired to report all consecutive stem cell transplanta-
tions and follow up once a year (Additional file 1).
Audits are routinely performed to determine the accur-
acy of the data. We included in the analysis patients af-
fected by AML older than 18 at diagnosis, who received
either auto-HSCT, 10/10 UD-HSCT, or 9/10 UD-HSCT
in CR1 as first transplant between January 2005 and
December 2013. Patients having secondary AML were
excluded. Only patients with available cytogenetic data
and allelic HLA typing for A, B, C, DRB1, and DQB1
(for UD-HSCT) were included. Good risk was defined as
t(8,21), inv(16)/t(16;16), or normal karyotype in the pres-
ence of NPM1 mutation without fms-like tyrosine
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kinase-internal tandem duplication (FLT3-ITD). Poor risk
was defined as −7, abnl (17p) −5/5q−, inv(3q)/t(3;3), t(6;9),
t(v;11)(v;q23), MLL rearranged except of t(9;11)(p22;q23),
complex karyotype, or normal karyotype in the pres-
ence of FLT3-ITD. Intermediate risk was defined as
t(9;11)(p22;q23), normal karyotype without NPM1 or
FLT3-ITD, or the absence of abnormalities categorized
as good or poor risk [10]. One hundred and twenty pa-
tients receiving auto-HSCT, 217 10/10 UD-HSCT, and
60 9/10 UD-HSCT had normal karyotype and wild-type
FLT3 (wtFLT3) and were analyzed separately as “inter-
mediate wtFLT3” group. Nine hundred and forty-two
patients (504 auto-HSCT, 333 10/10 UD-HSCT, and
105 9/10 UD-HSCT) had normal karyotype and un-
known molecular markers and were therefore assigned
to the intermediate-risk group. Patients from 283 trans-
plant centers were included; 83 centers reported both
auto-HSCT and UD-HSCT. One thousand six hun-
dred thirteen patients were transplanted in centers
having reported both auto-HSCT (n = 890) and UD-
HSCT (n = 723), while 1266 patients in centers having re-
ported only auto-HSCT (n = 787) or UD-HSCT.
Endpoint definitions and statistical analysis
Endpoints were relapse incidence (RI), non-relapse mor-
tality (NRM), leukemia-free survival (LFS), and overall
survival (OS). Cumulative incidences of relapse and
NRM were calculated from the date of transplant to the
date of relapse or death, respectively, with the other
events being the competing risk. LFS was defined as the
interval from transplant to either relapse or death. OS
was defined as the time between the date of transplant
and the date of death.
The main patient characteristics were compared using
Mann-Whitney test for quantitative variables, chi-square
test, or Fisher’s exact test for categorical variables. We
used propensity score (PS) weighting to control for pre-
treatment imbalances on observed variables. The follow-
ing factors were included in the PS model: age, year of
transplant, interval diagnosis transplant, number of
induction courses to reach CR1 (1 vs more than 1), and
cytogenetic risk. PS estimation was performed using
generalized boosted models [11]. As the research ques-
tion focused on the effectiveness of 10/10 UD-HSCT or
9/10 UD-HSCT if it were to replace auto-HSCT for pa-
tients having the same characteristics of those actually
receiving auto-HSCT, we weighted the 10/10 UD-HSCT
and 9/10 UD-HSCT groups to match the auto-HSCT
group, by estimating the average treatment effect among
the treated (ATT), auto-HSCT being the treated group.
The ATT weights equal one for auto-HSCT, and it
equals the ratio of the PS to one minus the PS in the
two UD-HSCT groups. In summary, each patient that
underwent UD-HSCT received a weight inversely
proportional to his probability of receiving an auto-
graft. Therefore, patients receiving UD-HSCT that
showed significantly different characteristics compared
to average autografted patients had a low contribution
in the comparisons. We checked the balance between
the groups looking to ATT-weighted means. Then, we
used pairwise ATTs to fit weighted Kaplan-Meier and
Cox models separately for auto-HSCT vs 10/10 UD-
HSCT and auto-HSCT vs 9/10 UD-HSCT, adjusting
for stem cell source (bone marrow or peripheral blood
stem cells) and conditioning regimen (total body
irradiation-based or not). The same procedure was re-
peated for each cytogenetic-risk group. Finally, we
looked to the subgroup of patients with intermediate
cytogenetics and wild-type FLT3, adding the time
interval from CR1 to transplant to the PS model. All
the results were checked by performing a subanalysis
excluding the fourth percentile for the interval from
diagnosis to transplant, obtaining consistent results.
All tests were two-sided. The type I error rate was
fixed at 0.05 for determination of factors associated
with time to event. Analyses were performed using the
R statistical software version 3.2.3; PS analysis was
performed using the mnps function of the Twang
package and weighted analyses using the survey pack-
age [12].
Results
Patient characteristics
The total number of patients who received either auto-
HSCT or UD-HSCT for AML in CR1 between 2005 and
2013 and reported to the EBMT was 8943 (3161 auto-
HSCT and 5782 UD-HSCT). One thousand nine hun-
dred and fifty-eight patients were excluded from the
analysis due to incomplete data about HLA typing.
Ninety-six patients were excluded as received UD-HSCT
which was 8/10 HLA-matched or inferior, leading to a
total number of 6889 patients available for analysis of
outcome (3161 auto-HSCT, 2921 10/10 UD-HSCT, and
807 9/10 UD-HSCT). Finally, 4010 patients were subse-
quently excluded due to incomplete data about cytogen-
etics, leading to a final number of 2879 patients included
in the propensity score model. Among them, 1202 re-
ceived auto-HSCT, 1302 10/10 UD-HSCT, and 375 9/10
UD-HSCT, respectively. Median follow-up was 45, 36,
and 34 months for auto-HSCT, 10/10 UD-HSCT, and
9/10 UD-HSCT, respectively. Median age at transplant
was higher for 10/10 UD-HSCT (51 years) compared to
9/10 UD-HSCT and auto-HSCT (49 years for 9/10 UD-
HSCT and auto-HSCT, p = 0.004). Interval from diag-
nosis to transplant was longer for UD-HSCT (174 and
177 days for 10/10 UD-HSCT and 9/10 UD-HSCT, re-
spectively) compared to auto-HSCT (158 days, p < 10−4).
Patients who received UD-HSCT showed more frequently
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poor-risk cytogenetics (16, 47, and 49 % for auto-HSCT, 10/
10 UD-HSCT, and 9/10 UD-HSCT, respectively, p < 10−4)
and were more likely to have received a total body irradiation
(TBI)-based conditioning (p < 10−4). Median year of trans-
plant was more recent for UD-HSCT (2010) compared to
auto-HSCT (2008, p < 10−4). Stem cell source was peripheral
blood stem cells for 96 % of auto-HSCT, 80 % of 10/10 UD-
HSCT, and 85 % of 9/10 UD-HSCT patients (p < 10−4).
Among the UD-HSCT cohort, 813 patients received a mye-
loablative (MAC) conditioning (619 in the 10/10 UD-HSCT
and 194 in the 9/10 UD-HSCT group, respectively), while
857 received a reduced-intensity (RIC) conditioning
regimen (677 in the 10/10 UD-HSCT and 180 in the
9/10 UD-HSCT group). The characteristics of the pa-
tients are summarized in Table 1.
Since patient and disease characteristics were unevenly
distributed among the transplant categories (auto-HSCT,
10/10 UD-HSCT, and 9/10 UD-HSCT), we fit a propen-
sity score model generating ATT-weighted means for
the three groups. After weighting, group characteristics
were similar in terms of all baseline covariates used for
PS estimation (Table 2).
Outcome in the overall population
In the global population, the 3-year NRM rate was
significantly lower for auto-HSCT compared to 10/10
UD-HSCT and 9/10 UD-HSCT (being 4 ± 2, 13 ± 2, and
21 ± 3 %, respectively; Fig. 1a), as evidenced by PS-
weighted Cox analysis (10/10 UD-HSCT vs auto-HSCT:
HR 3.1, p < 10−5, 95 % CI 2–4.7; 9/10 UD-HSCT vs
auto-HSCT: HR 4.5, p < 10−5, 95 % CI 2.5–8.1, Table 3).
The 3-year RI was higher following auto-HSCT (49 ±
3 %) compared to 10/10 UD-HSCT (29 ± 3 %) and 9/10
UD-HSCT (23 ± 3 %), as evidenced by PS-weighted Cox
analysis (10/10 UD-HSCT vs auto-HSCT: HR 0.5, p <
10−5, 95 % CI 0.4–0.7; 9/10 UD-HSCT vs auto-HSCT:
HR 0.5, p = 0.0016, 95 % CI 0.3–0.8; Fig. 1b).
Fully matched UD-HSCT was associated with the best
3-year LFS (58 ± 3 %), while LFS rates were not statisti-
cally different between auto-HSCT and 9/10 UD-HSCT,
being 48 ± 3 and 55 ± 3 %, respectively (10/10 vs auto-
HSCT: HR 0.7, p = 0.0016, 95 % CI 0.6–0.9; 9/10 vs
auto-HSCT: HR 0.8, p = 0.2, 95 % CI 0.5–1.1; Fig. 1c).
The 3-year OS was not statistically different across the
groups, being 64 ± 3, 63 ± 3, and 58 ± 4 % for auto-
HSCT, 10/10 UD-HSCT, and 9/10 UD-HSCT, respect-
ively (10/10 vs auto-HSCT: HR 0.98, p = 0.84, 95 % CI
0.8–1.2; 9/10 vs auto-HSCT: HR 1.1, p = 0.49, 95 % CI
0.8–1.7; Fig. 1d).
Outcome by cytogenetic risk
In the favorable risk group, we could only compare out-
come of auto-HSCT to 10/10 UD-HSCT, as the number
of 9/10 UD-HSCT transplants was too limited. Auto-
HSCT was associated with a 3-year RI rate of 36 ± 5 %,
while 10/10 UD-HSCT provided a 3-year RI of 19 ± 5 %,
which was significantly lower in PS-weighted Cox ana-
lysis (10/10 UD-HSCT vs auto-HSCT: HR 0.5, p = 0.018,
95 % CI 0.3–0.9). There was a trend for better 3-year
LFS following 10/10 UD-HSCT compared to auto-HSCT,
being 72 ± 6 and 59 ± 5 %, respectively (HR 0.7, p = 0.1,
95 % CI 0.4–1.1; Fig. 2a). Overall survival at 3 years was not
significantly different, being 78 ± 4 % for auto-HSCT and
77 ± 5 % for 10/10 UD-HSCT (10/10 UD-HSCT vs auto-
HSCT: HR 1.1, p = 0.7, 95 % CI 0.6–2; Fig. 2b).
Intermediate-risk AML represented the largest sub-
population in our survey and was the cohort in which
the characteristics of the three groups showed the great-
est overlap. In this subgroup, auto-HSCT was associated
with higher relapse incidence (51 ± 4 %) compared to
10/10 UD-HSCT (30 ± 5 %) and 9/10 UD-HSCT (21 ±
4 %), as evidenced by PS-weighted Cox analysis (10/10
UD-HSCT vs auto-HSCT: HR 0.5, p < 10−5, 95 % CI 0.4–
0.7; 9/10 UD-HSCT vs auto-HSCT: HR 0.4, p = 0.004,
95 % CI 0.3–0.8). NRM rates were significantly lower for
auto-HSCT compared to 10/10 UD-HSCT and 9/10 UD-
HSCT, being 4 ± 2, 16 ± 3, and 34 ± 5 %, respectively
(10/10 UD-HSCT vs auto-HSCT: HR 3.6, p < 10−4, 95 %
CI 2–6.4; 9/10 UD-HSCT vs auto-HSCT: HR 9.4, p < 10−5,
95 % CI 4.9–18). This translated to an advantage in terms
of LFS for 10/10 UD-HSCT (54 ± 4 %) but not for 9/10
UD-HSCT (45 ± 5 %) over auto-HSCT (45 ± 4 %), as evi-
denced by PS-weighted Cox analysis (10/10 UD-HSCT vs
auto-HSCT: HR 0.7, p = 0.01, 95 % CI 0.6–0.9; 9/10 UD-
HSCT vs auto-HSCT: HR 1.1, p = 0.7, 95 % CI 0.7–1.6;
Fig. 3a). Notably, 3-year OS did not differ between auto-
HSCT (60 ± 4 %) and 10/10 UD-HSCT (60 ± 5 %), while it
was significantly lower for 9/10 UD-HSCT (48 ± 4 %), as
evidenced by PS-weighted COX analysis (10/10 UD-
HSCT vs auto-HSCT: HR 0.98, p = 0.9, 95 % CI 0.7–1.3;
9/10 UD-HSCT vs auto-HSCT: HR 1.6, p = 0.049, 95 %
CI 1.001–2.5; Fig. 3b).
Within the intermediate-risk cohort, we further ana-
lyzed the outcome of patients bearing wild-type FLT3; in
this subpopulation, we could only compare auto-HSCT
to 10/10 UD-HSCT, as the number of 9/10 UD-HSCT
transplants was too limited to allow for propensity score
weighting. RI rate was significantly higher for auto-
HSCT compared to 10/10 UD-HSCT, being 55 ± 10 and
31 ± 12 %, respectively (10/10 UD-HSCT vs auto-HSCT:
HR 0.5, p = 0.04, 95 % CI 0.3–0.9). Matched UD-HSCT
was associated with a trend for better LFS compared to
auto-HSCT, being 61 ± 11 and 41 ± 8 %, respectively
(10/10 UD-HSCT vs auto-HSCT: HR 0.6, p = 0.10, 95 %
CI 0.4–1.1), while no significant difference was observed
in terms of OS (66 ± 10 and 60 ± 8 % for 10/10 UD-HSCT
and auto-HSCT, respectively; 10/10 UD-HSCT vs auto-
HSCT: HR 0.95, p = 0.88, 95 % CI 0.5–1.7).
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Table 1 Patient, disease, and transplant characteristics
Type of transplant
Variable Auto-HSCT 10/10 UD-HSCT 9/10 UD-HSCT p
Number (total: 2879) 1202 1302 375
Gender, n (%) 0.046
Male 681 (57) 694 (53) 188 (50)
Female 518 (43) 608 (47) 187 (50)
WBC at diagnosis (×109/l), median (range) 13.8 (0.3–820) 10 (0.3–900) 9.9 (0.2–790) 0.32
Missing 592 308 99
Cytogenetic risk, n (%) <10−4
Good 392 (33) 137 (11) 26 (7)
Intermediate 624 (51) 550 (42) 165 (44)
Poor 186 (16) 615 (47) 184 (49)
Molecular aberrations, n (%)
NPM1 mutation 0.001
Absent 64 (34) 150 (49) 41 (53)
Present 124 (66) 154 (51) 37 (47)
Missing 438 280 96
FLT3-ITD <10−4
Absent 159 (70) 178 (48) 48 (44)
Present 68 (30) 197 (52) 61 (56)
Missing 399 209 66
CEBPA mutation 0.07
Absent 40 (82) 109 (90) 33 (97)
Present 9 (18) 12 (10) 1 (3)
Missing 577 463 140
No. of induction courses to reach CR1, n (%) <10−4
1 617 (51) 722 (56) 187 (50)
More than 1 195 (17) 408 (31) 122 (33)
Missing 390 (32) 172 (13) 66 (17)
MRD status at transplant 0.53
MRD negative 361 (79) 352 (73) 81 (76)
MRD positive 99 (21) 132 (27) 26 (24)
Missing 742 818 268
Median age at transplant, years (range) 49 (18–78) 51 (18–76) 49 (18–69) 0.004
Median interval diagnosis transplant, days (range) 158 (75–813) 174 (66–997) 177 (83–766) <10−4
Median interval CR1 transplant, days (range) 109 (21–365) 115 (18–447) 121 (21–348) 0.41
Missing 390 172 66
Median year of transplant (range) 2008 (05–13) 2010 (05–13) 2010 (05–13) <10−4
Stem cell source, n (%) <10−4
BM 53 (4) 258 (20) 58 (16)
PBSCs 1149 (96) 1044 (80) 317 (84)
TBI-including conditioning, n (%) <10−4
No 1112 (93) 936 (72) 262 (70)
Yes 85 (7) 364 (28) 113 (30)
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In the poor-risk group, RI rate was once again signifi-
cantly higher for auto-HSCT compared to 10/10 UD-
HSCT and 9/10 UD-HSCT, being 64 ± 8, 34 ± 9, and 40
± 9 %, respectively (10/10 UD-HSCT vs auto-HSCT: HR
0.5, p = 0.0003, 95 % CI 0.3–0.7; 9/10 UD-HSCT vs
auto-HSCT: HR 0.7, p = 0.08, 95 % CI 0.4–1.1). Fully
matched UD-HSCT was associated with better LFS
compared to auto-HSCT, being 52 ± 8 and 34 ± 6 %,
respectively (10/10 UD-HSCT vs auto-HSCT: HR 0.7, p
= 0.018, 95 % CI 0.5–0.9), while LFS was not statistically
Table 1 Patient, disease, and transplant characteristics (Continued)
Conditioning intensity, n (%)
MAC – 619 (48) 194 (52)
RIC – 677 (52) 180 (48)
Median follow-up, months (range) 45 (1–128) 36 (1–119) 25 (1–113)
Legend: BM bone marrow, CEBPA CCAAT/enhancer-binding protein alpha, CR1 first complete remission, FLT3-ITD fms-like tyrosine kinase-internal tandem duplication,
MAC myeloablative, MRD minimal residual disease, NPM1 nucleophosmin, PBSCs peripheral blood stem cells, RIC reduced-intensity, TBI total-body irradiation, WBC white
blood cells
Table 2 ATT-weighted means for transplant groups
Weighted means p
Variable Auto-HSCT 10/10 UD-HSCT 9/10 UD-HSCT 10/10 UD-HSCT vs
auto-HSCT
9/10 UD-HSCT vs
auto-HSCT
Global population
Median age at transplant, years 47 46 47 0.84 1.00
Median year of transplant 2008 2008 2008 0.66 0.88
Median interval diagnosis transplant (days) 178 179 179 0.80 0.49
Good-risk cytogenetics (%) 33 31 30 1.00 1.00
Poor-risk cytogenetics (%) 15 17 19 1.00 1.00
More than 1 induction to achieve CR1 (%) 16 18 17 0.7 0.91
By cytogenetic risk
Good risk
Median age at transplant, years 44 44 n.a.a 0.96 n.a.
Median year of transplant 2009 2009 n.a. 0.56 n.a.
Median interval diagnosis transplant (days) 186 188 n.a. 1.00 n.a.
More than 1 induction to achieve CR1 (%) 0.01 0.09 n.a. 0.84 n.a.
Intermediate risk
Patient age (years) 48 48 49 0.96 0.39
Year of transplant 2008 2008 2008 0.36 0.83
Interval diagnosis transplant (days) 174 181 183 0.51 0.90
More than 1 induction to achieve CR1 (%) 19 22 17 0.36 0.91
Intermediate-risk wtFLT3
Patient age (years) 46 48 n.a. 0.75 n.a.
Year of transplant 2008 2009 n.a. 0.46 n.a.
Interval diagnosis transplant (days) 118 115 n.a. 0.93 n.a.
More than 1 induction to achieve CR1 (%) 17 21 n.a. 0.81 n.a.
Poor risk
Patient age (years) 50 50 50 1.00 0.93
Year of transplant 2008 2008 2009 0.87 0.11
Interval diagnosis transplant (days) 172 170 173 1.00 0.91
More than 1 induction to achieve CR1 (%) 24 25 27 0.81 0.77
Legend: ATT average treatment effect among the treated, CR1 first complete remission, wtFLT3 wild-type FLT3
aIn good risk and intermediate wtFLT3 categories, only auto-HSCT and 10/10 UD-HSCT were analyzed, as the number of 9/10 UD-HSCT transplants resulted
too limited
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different between auto-HSCT and 9/10 UD-HSCT, being
34 ± 6 and 38 ± 8 % (9/10 UD-HSCT vs auto-HSCT: HR 1,
p = 0.88, 95 % CI 0.7–1.5; Fig. 4a). Overall survival was not
statistically different across transplant groups, being 50
± 7, 54 ± 8, and 41 ± 8 % for auto-HSCT, 10/10 UD-
HSCT, and 9/10 UD-HSCT, respectively (10/10 UD-
HSCT vs auto-HSCT: HR 0.9, p = 0.4, 95 % CI 0.6–1.2;
9/10 UD-HSCT vs auto-HSCT: HR 1.3, p = 0.2, 95 % CI
0.9–1.9; Fig. 4b).
Outcome in the global registry population
(6889 patients), unadjusted
As previously stated, from the starting 6889 patients
receiving auto-HSCT, 10/10 UD-HSCT, or 9/10 UD-
HSCT reported to the EBMT, 4010 patients were ex-
cluded due to incomplete cytogenetic data. We herein
report the unadjusted results of outcome of all AML
patients receiving auto-HSCT, 10/10 UD-HSCT, or 9/10
UD-HSCT in CR1 between 2005 and 2013 included in the
EBMT registry: the 3-year LFS was 47 ± 2 % for auto-
HSCT, 54 ± 2 % for 10/10 UD-HSCT, and 47 ± 4 % for
9/10 UD-HSCT, while the 3-year OS was 59 ± 2, 58 ± 2,
and 50 ± 4 %, respectively.
Outcome after the second transplant
Three hundred patients (25 % of the auto-HSCT group)
received a subsequent allo-HSCT for leukemic relapse
after auto-HSCT. Cytogenetic risk was good in 26 %,
intermediate in 53 %, and poor in 21 % of the patients.
With a median follow-up of 3.5 years after the second
allograft, 2-year OS was 50 ± 6 %. OS was significantly
affected by cytogenetic risk, being 61 ± 6 % in good risk,
45 ± 4 % in intermediate risk, and 49 ± 6 % in poor-risk
patients (p = 0.019).
Conversely, 107 patients (7 % of the UD-HSCT group)
underwent a second allo-HSCT for disease relapse post-
first UD-HSCT transplant (79 in the 10/10 UD-HSCT
group and 28 in the 9/10 UD-HSCT group). In this popu-
lation, 2-year OS after second transplant was 25 ± 10 %.
Fig. 1 Outcome by type of transplant in the global population. The cumulative incidence of non-relapse mortality (a) and relapse (b) by
transplant type; the probability of leukemia-free survival (c) and overall survival (d) in the global population. Kaplan-Meier curves and Cox
analysis are weighted for propensity score; Cox analysis is further adjusted for kind of conditioning and stem cell source
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Acute and chronic graft-vs-host disease
Incidence of grade II–IV acute graft-vs-host disease
(aGVHD) in patients receiving UD-HSCT was 27 ± 2 %
in 10/10 UD-HSCT and 31 ± 4 % in 9/10 UD-HSCT,
with no significant difference between the two groups (p
= 0.1). Cumulative incidence of chronic graft-vs-host
disease (cGVHD) at 2 years was 42 % in 10/10 UD-
HSCT and 40 % in 9/10 UD-HSCT with no significant
difference (p = 0.7). Incidence of severe (grade 3)
cGVHD was also not different between the two cohorts,
being 20 ± 2 and 17 ± 4 % in 10/10 UD-HSCT and 9/10
UD-HSCT, respectively (p = 0.16).
Table 3 PS-weighted Cox analysis of transplant outcomes, adjusted for kind of conditioning and stem cell source
Type of transplant NRM RI LFS OS
HR 95 % CI p HR 95 % CI p HR 95 % CI p HR 95 % CI p
Global population
Auto-HSCT (reference) 1 1 1 1
10/10 UD-HSCT 3.1 2–4.7 <10−5 0.5 0.4–0.7 <10−5 0.7 0.6–0.9 0.0016 0.97 0.8–1.2 0.84
9/10 UD-HSCT 4.5 2.5–8.1 <10−5 0.5 0.3–0.8 0.0016 0.8 0.6–1.1 0.227 1.1 0.8–1.7 0.49
By cytogenetic risk
Good risk
Auto-HSCT (reference) 1 1 1 1
10/10 UD-HSCT 1.9 0.7–5.5 0.24 0.5 0.3–0.9 0.018 0.7 0.4–1.1 0.1 1.1 0.6–2 0.7
Intermediate risk
Auto-HSCT (reference) 1 1
10/10 UD-HSCT 3.6 2–6.4 <10−4 0.5 0.4–0.7 <10−5 0.7 0.6–0.9 0.01 0.98 0.7–1.3 0.9
9/10 UD-HSCT 9.4 4.9–18 <10−5 0.4 0.3–0.8 0.004 1.1 0.7–1.6 0.7 1.6 1.001–2.5 0.049
Intermediate wtFLT3
Auto-HSCT (reference) 1 1 1 1
10/10 UD-HSCT 2.8 0.8–9.8 0.11 0.5 0.29–0.98 0.04 0.6 0.4–1.1 0.10 0.95 0.53–1.7 0.88
Poor risk
Auto-HSCT (reference) 1 1 1 1
10/10 UD-HSCT 6.3 2.3–17.4 0.0004 0.5 0.3–0.7 0.0003 0.7 2.3–17.4 0.0004 0.9 0.6–1.2 0.4
9/10 UD-HSCT 11.7 4–34.7 <10−5 0.7 0.4–1 0.08 1.03 0.7–1.5 0.88 1.3 0.9–1.9 0.2
Legend: wtFLT3 wild-type FLT3
Fig. 2 Leukemia-free survival and overall survival by type of transplant in good-risk patients. The probability of leukemia-free survival (a) and
overall survival (b) in good-risk patients
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Discussion
AML post-remission strategy remains largely debated.
Different approaches are available, and recommenda-
tions are quickly mutating owing to continuous refining
of risk stratification [13, 14], improvements in transplant
preparatory regimens and GVHD prophylaxis [5, 15],
and widening of the donor pool [16]. Therefore, when
counseling a patient with AML in CR1, it is often diffi-
cult to make a straightforward statement.
Several randomized trials have shown significantly bet-
ter LFS for auto-HSCT compared to chemotherapy as
consolidation of remission in AML [17–20]. In the only
prospective study conducted in the last decade, Vellenga
et al. observed a reduced relapse rate following auto-
HSCT when compared to chemotherapy [19]; the same
group recently reported better survival following auto-
HSCT in intermediate-risk AML [8]. Of note, in a recent
report of a large randomized trial, Stone and colleagues
Fig. 3 Leukemia-free survival and overall survival by type of transplant in intermediate-risk patients. The probability of leukemia-free survival
(a) and overall survival (b) in intermediate-risk patients
Fig. 4 Leukemia-free survival and overall survival by type of transplant in poor-risk patients. The probability of leukemia-free survival (a) and
overall survival (b) in poor-risk patients
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[21] showed a significant survival benefit with the
addition of the multi-target kinase inhibitor midostaurin
to standard chemotherapy for AML patients bearing
FLT3-ITD or TKD aberrations, an important finding
that hopefully will pave its way into daily clinical
practice.
Globally, donor vs no donor studies [22] and meta-
analyses [23] evidenced a survival benefit for allo-HSCT
over auto-HSCT in intermediate and poor cytogenetic-
risk groups, but not in good-risk AML, in which the
high NRM rate offsets the advantage of stronger anti-
leukemic activity carried by allo-HSCT [24]. Neverthe-
less, donor vs no donor analyses suffered from biologic
randomization bias; further, most studies combined
patients receiving auto-HSCT and conventional chemo-
therapy in the no donor arm and included mostly young
patients that received grafts from MSD, which accounts
for a minority of transplants performed today. Further-
more, in some recent observations, auto-HSCT has
been shown to provide similar survival to allo-HSCT
from both sibling and unrelated donors [7–9]. None-
theless, there is scarcity of literature confronting auto-
HSCT to UD-HSCT, especially mismatched unrelated
donor (MMUD).
We took therefore advantage of the EBMT-ALWP
registry and analyzed a large homogeneous cohort of pa-
tients with AML in CR1. To mitigate the impact of the
intrinsic limitations of a registry-based survey, such
transplant-selection bias and disease risk imbalances be-
tween the groups, we performed a propensity score ad-
justed analysis, weighting transplant groups for the most
significant patient characteristics, and further adjusting
for kind of conditioning and stem cell source. Within
this model, patients who received a UD-HSCT having
significantly different characteristics compared to auto-
grafted patients had a very low impact on estimation of
the outcome. In addition, we analyzed separately pa-
tients with good-, intermediate-, and poor-risk AML, to
further elude the bias of cytogenetic risk unbalance. To
better interpret the results obtained with PS-weighting
analysis, it is worth noting that this model produces
outcome results (i.e., LFS and OS) which, if compared
to the crude (unadjusted) LFS and OS, are consistent
for auto-HSCT, while better for UD-HSCT. This is a
consequence of the rationale of the method itself which
selects, among the UD-HSCT population, the patients
which present similar characteristics to auto-HSCT
patients.
Our data suggest that fully matched UD-HSCT pro-
vides better leukemia control but similar survival com-
pared to auto-HSCT in AML in CR1. Further,
mismatched UD-HSCT appears to be associated with
inferior survival compared to auto-HSCT in patients
bearing intermediate-risk cytogenetics.
The widespread availability of high-resolution HLA
typing has greatly improved outcome of UD transplants,
and results of allo-HSCT from fully HLA-matched UD
are today overlapping with MSD outcome [25, 26]. How-
ever, MMUD transplants are associated with increased
morbidity and mortality; in fact, higher incidence of
both acute [27] and chronic [28, 29] GVHD rates have
been described following mismatched transplants. In
addition, NRM risk tends to increase proportionally to
the number of HLA disparities [30–33], although im-
proved outcome of MMUD transplants has recently
been reported following RIC regimens [4]. Finally, recent
developments in haploidentical transplantation are be-
ginning to bring into question the choice of a mis-
matched unrelated over a haploidentical donor, when
available [5].
Auto-HSCT results, on the other hand, have pro-
gressively improved. Switch of stem cell source from
BM to peripheral blood stem cells (PBSCs) and refine-
ments in preparatory regimens [15] have led to faster
hematopoietic recovery, reduced mortality and satis-
factory outcome; in a recent observation, Gorin et al.
[34] reported a 2-year LFS of 61 % following auto-HSCT
prepared with a busulfan-melphalan conditioning.
In a previous EBMT survey conducted on a cohort of
patients affected by MDS or secondary AML, Al-Ali et
al. [35] observed similar 3-year LFS and OS for 8/8 UD-
HSCT and auto-HSCT; a landmark analysis revealed bet-
ter outcome with MUD-HSCT only for patients surviv-
ing beyond 6 months since transplant. A more recent
study by Cho et al. [36] analyzed a small population of
young intermediate-risk AML patients undergoing either
MSD, 8/8 UD-HSCT, or auto-HSCT; the authors re-
ported an advantage in terms of LFS for 8/8 UD-HSCT
over auto-HSCT, with no significant difference in OS.
Similarly, in a very recent observation by Mizutani et al.
[37], MUD-HSCT provided lower RI but no survival ad-
vantage over auto-HSCT in patients with intermediate-
risk AML in CR1.
In the current study, we observed a significantly
lower NRM and higher RI for auto-HSCT compared to
UD-HSCT. In the global population, auto-HSCT pro-
vided an acceptable 3-year LFS rate of 48 %, which was
significantly lower compared to 10/10 UD-HSCT, but
not statistically different from 9/10 UD-HSCT. None-
theless, the better leukemia control provided by fully
matched UD-HSCT did not translate in a survival
benefit, as OS at 3 years was similar for auto-HSCT and
10/10 UD-HSCT, while slightly lower for 9/10 UD-
HSCT, this difference being not statistically significant.
In the subgroup analysis stratified by cytogenetic risk,
auto-HSCT provided a particularly good outcome in
patients with favorable risk AML, being 3-year LFS and
OS rates 59 and 78 %, respectively; those results are
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consistent with previous reports [38]. There is evidence
indicating that auto-HSCT is able to significantly re-
duce relapse risk in AML with favorable cytogenetics,
which still carry disease recurrence rates up to 35–40 %
following conventional chemotherapy, with a particular
risk for core-binding factor (CBF) AML with adverse
prognostic features [39] or positive MRD after consolida-
tion chemotherapy [40]. Further, there is data suggest-
ing that in NPM1-mutated and CEBPA double-mutated
(CEBPAdm) AML, the high chemosensitivity of the dis-
ease might be exploited with auto-HSCT intensification
[41, 42]. Awaiting for MRD-driven prospective trials
comparing high-dose cytarabine and auto-HSCT in this
setting, these findings support auto-HSCT as a valid
strategy for consolidation of remission in patients with
good-risk cytogenetics.
Intermediate risk represents the gray zone of AML
guidelines. The role of allo-HSCT in these patients is
not as clear as in poor-risk category [23], and it is be-
coming even more controversial with the incorporating
of MRD data in clinical algorithms. In 2014, auto-
HSCT was removed from NCCN recommendations in
intermediate-risk AML, and today, most physicians
would perform allo-HSCT in this setting, supported by
a clear advantage in terms of LFS over auto-HSCT and
conventional chemotherapy [23, 24]. However several
studies, including recent analyses [7–9], failed to ob-
serve a survival advantage of allo-HSCT over auto-
HSCT in intermediate-risk AML.
In our study, intermediate risk represented the largest
subgroup, accounting for approximately half of all
patients included in the analysis. Moreover, it was the
cohort in which the characteristics of the three groups
showed the greatest overlap and was therefore the main
focus of our analysis. Forty-five percent of intermediate-
risk patients who received auto-HSCT were alive and
leukemia-free at 3 years after transplant. Further, in this
subpopulation, matched UD-HSCT provided the best
LFS, while no significant difference could be observed
between auto-HSCT and 10/10 UD-HSCT in terms of
OS. Similarly, in a subgroup analysis of patients bearing
intermediate cytogenetics and wtFLT3, 10/10 UD-HSCT
showed a trend for better LFS without a survival advan-
tage over auto-HSCT. Notably, in the PS-weighted analysis
conducted on the whole group of intermediate-risk pa-
tients, auto-HSCT provided better OS compared to 9/10
UD-HSCT. In a recent report by Cornelissen et al. [8], allo-
HSCT was associated with better LFS compared to auto-
HSCT, but similar OS was observed in intermediate-risk
patients. In that study, only MSD or 8/8 UD-HSCT were
allowed in intermediate-risk group; therefore, our observa-
tion of a survival advantage of auto-HSCT over MMUD in
intermediate-risk AML can be interpreted as not in contra-
diction with previous data.
However, the good survival following auto-HSCT
should be analyzed more carefully. Indeed while, as ex-
pected, OS rates of UD-HSCT were approximately 5 %
higher than the respective LFS rates, in intermediate-risk
patients receiving auto-HSCT, 3-year LFS was 45 %,
while OS was as high as 60 %. This striking difference
can be mostly explained as a consequence of successful
salvage treatment for many patients relapsed after
auto-HSCT. In fact, a considerably great proportion of
patients who experienced disease recurrence following
auto-HSCT were effectively rescued and received a
subsequent allo-HSCT, which provided a 2-year OS of
approximately 50 %.
Nevertheless, relapse incidence following auto-HSCT
is disturbingly high and remains the biggest concern
about this approach. We observed a 3-year cumulative
RI of 51 % in intermediate-risk patients receiving an
autograft. Most patients experienced disease recurrence
within 2 years, but late relapses were noticed, as previ-
ously reported [15, 43]. The dynamic risk stratification
allowed by MRD assessment is becoming crucial in
AML post-remission setting [44, 45] and might help to
identify the best candidates for auto-HSCT; in fact,
auto-HSCT has been already proven able to provide
long-term remission in MRD-negative APL [46] and
ALL [47]. In the AML setting, this concept is currently
under investigation in a prospective-MRD driven clinical
trial by the Gruppo Italiano Malattie EMatologiche
dell’Adulto (GIMEMA-AML1310) which results are
awaiting.
Finally, quality of life of transplant survivors should be
taken into account, since leukemia cure does not always
coincide with full health. Different studies highlighted
the high incidence of late effects after allo-HSCT, mostly
but not only related to chronic GVHD [48]. In our sur-
vey, almost 40 % of UD transplant survivors experienced
cGVHD, which was severe in approximately half of
them. These data should be taken into consideration
when comparing survival of auto-HSCT and UD-HSCT
[49].
The current analysis has several limitations. First, as
may occur in any multicenter registry study, the three
transplant groups were unevenly balanced in terms of
patient characteristics, and the retrospective design did
not allow to study the reason for choosing UD-HSCT or
auto-HSCT, which may vary according to physician and
center strategy. We try to address those limitations fit-
ting a PS-weighting model in order to control for the
most significant pre-transplant covariates and further
stratifying the analysis by cytogenetic risk. Additional
limitations that are the consequence of being a registry-
based study are missing data about molecular aberra-
tions (i.e., NPM1, FLT3-ITD, and CEBPA status) and
MRD status for part of the patients. However, it should
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be noted that NPM1 and FLT3 status was available in
approximately one third of the patients with normal
karyotype, which enabled us to perform an acceptable
even if not optimal risk stratification.
Conclusions
In conclusion, given the limitations of the study, in AML
patients in CR1 lacking a MSD, 10/10 UD-HSCT signifi-
cantly improves LFS, but this advantage does not translate
in better OS compared to auto-HSCT. In intermediate-
risk population, autologous transplant should be consid-
ered as a valid option, especially for patients lacking a fully
HLA-matched donor, as better survival appears to be
provided by auto-HSCT compared to mismatched UD
transplant. Further, autologous transplant provided an
encouraging outcome in favorable risk AML. These
data may suggest that the current strategy for manage-
ment of AML in CR1 should incorporate auto-HSCT in
patients with good- and intermediate-risk cytogenetics,
especially for those lacking a fully HLA-matched donor.
Obviously, this strategy should be examined in well-
designed multicenter randomized studies incorporating
MRD status and center experience as well as novel ap-
proaches for post-transplantation maintenance as mid-
ostaurin or other novel compounds.
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